Hematology. American Society of Hematology. Education Program最新文献_第10页

Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity. 减轻、监测和管理长期化疗和放疗引起的心脏毒性。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000342

Wendy Bottinor, Eric J Chow

{"title":"Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity.","authors":"Wendy Bottinor, Eric J Chow","doi":"10.1182/hematology.2022000342","DOIUrl":"https://doi.org/10.1182/hematology.2022000342","url":null,"abstract":"Five-year survival for childhood cancer now exceeds 85%. However, for many patients, treatment requires the use of intensive anthracycline-based chemotherapy and radiotherapy, both of which are associated with significant long-term cardiovascular toxicity. As such, late cardiovascular disease is now one of the leading causes of premature morbidity and mortality among childhood cancer survivors. Recent advances over the past decade have refined the cardiotoxic potential of various chemotherapeutics, and ongoing work seeks to determine the efficacy of various cardioprotective strategies in children receiving active cancer therapy. The development of risk prediction models offers an additional strategy to define risk for both newly treated and long-term survivors. Current screening strategies are primarily based on echocardiography, although there is active research investigating methods to further optimize screening through myocardial strain, cardiac magnetic resonance imaging, blood biomarkers, and genetics, along with the cost-effectiveness of different screening strategies. Active research is also underway investigating the efficacy of prevention strategies for childhood cancer survivors who have completed cancer therapy. This ranges from the use of medications to mitigate potential pathologic ventricular remodeling to reducing adverse and modifiable cardiovascular risk factors (eg, hypertension, dyslipidemia, insulin resistance, physical inactivity, tobacco exposure), many of which may be more common in cancer survivors vs the general population and are often underrecognized and undertreated in relatively young adult-aged survivors of childhood cancer.","PeriodicalId":12973,"journal":{"name":"Hematology. American Society of Hematology. Education Program","volume":"2022 1","pages":"251-258"},"PeriodicalIF":3.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820865/pdf/hem.2022000342.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10506393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"教育学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Perioperative hemostasis for patients with hemophilia. 血友病患者围手术期止血。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000387

Jacqueline N Poston, Rebecca Kruse-Jarres

引用次数: 1

Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura? 基于证据的迷你综述:卡普拉珠单抗是否应常规用于未选择的免疫性血栓性血小板减少性紫癜患者?

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000412

George Goshua, Pavan K Bendapudi

引用次数: 4

The burden of myeloma: novel approaches to disease assessment. 骨髓瘤的负担:疾病评估的新方法

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000348

Matthew Ho, Taxiarchis Kourelis

引用次数: 0

Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia. 基于证据的迷你综述:处理严重hla同种异体免疫患者难治性血小板减少症的策略。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000416

Debbie Jiang, Sandhya R Panch

引用次数: 0

Cellular therapy for multiple myeloma: what's now and what's next. 多发性骨髓瘤的细胞疗法:现在是什么，下一步是什么。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000396

Paula Rodriguez-Otero, Jesús F San-Miguel

{"title":"Cellular therapy for multiple myeloma: what's now and what's next.","authors":"Paula Rodriguez-Otero, Jesús F San-Miguel","doi":"10.1182/hematology.2022000396","DOIUrl":"https://doi.org/10.1182/hematology.2022000396","url":null,"abstract":"Despite significant improvement in the treatment of multiple myeloma (MM), a cure remains elusive, and patients failing proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies remain a challenge due to a lack of standard of care treatment and a dismal survival rate. The development of T-cell redirecting therapies, including bispecific T-cell engagers and chimeric antigen receptor (CAR) T cells, have transformed the outcome of triple-class exposed relapsed and refractory MM (RRMM). B-cell maturation antigen (BCMA) has proven to be an important target in MM, and BCMA-directed CAR T cells have shown unprecedented efficacy with a prolonged duration of response in a population with advanced RRMM, leading to the approval of 2 different BCMA CAR T-cell products. Still, and in contrast to prior experience in the field of CD19-directed CARs, no plateau has been seen in the survival curves, and relapses continue to occur. Therefore, further improvement is needed. Early use in the course of the disease as well as of next- generation CARs may further augment the efficacy of these therapies. In this review we address current state-of-the-art approved BCMA-directed CAR T-cell therapy in RRMM, as well as potential future developments focused on optimizing patient care and novel CAR designs.","PeriodicalId":12973,"journal":{"name":"Hematology. American Society of Hematology. Education Program","volume":"2022 1","pages":"180-189"},"PeriodicalIF":3.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820257/pdf/hem.2022000396.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10851373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"教育学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Novel platelet products including cold-stored platelets. 新型血小板产品，包括冷藏血小板。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000400

Dana V Devine

引用次数: 3

Diagnostic pitfalls and conundrums in type 1 von Willebrand disease. 1型血管性血友病的诊断陷阱和难题。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000389

Robert F Sidonio, Michelle Lavin

引用次数: 0

The consultant's guide to smoldering multiple myeloma. 阴燃型多发性骨髓瘤的顾问指南。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000355

Sigrun Thorsteinsdottir, Sigurdur Yngvi Kristinsson

引用次数: 2

Warm autoimmune hemolytic anemia and the best treatment strategies. 温热自身免疫性溶血性贫血及最佳治疗策略。

IF 3 3区教育学

Hematology. American Society of Hematology. Education Program Pub Date : 2022-12-09 DOI: 10.1182/hematology.2022000405

David J Kuter

{"title":"Warm autoimmune hemolytic anemia and the best treatment strategies.","authors":"David J Kuter","doi":"10.1182/hematology.2022000405","DOIUrl":"https://doi.org/10.1182/hematology.2022000405","url":null,"abstract":"Warm autoimmune hemolytic anemia (wAIHA) is characterized by evidence of red blood cell (RBC) hemolysis and a direct antiglobulin test positive for IgG and sometimes complement. While varying with the extent of the compensatory increase in RBC production, symptoms of anemia predominate, as does jaundice, the latter often exacerbated by concurrent Gilbert's syndrome. Initial treatment with corticosteroids is highly effective, with over 85% of patients responding but with less than one-third maintaining that response upon weaning. Subsequent rituximab administration in those failing corticosteroids provides complete remission in over 75% of patients and may be long-lasting. Over 50% of patients failing rituximab respond to erythropoiesis-stimulating agents or immunosuppressive agents. Splenectomy is best deferred if possible but does offer long-term remission in over two-thirds of patients. A number of new treatments for wAIHA (fostamatinib, rilzabrutinib, and FcRn inhibitors) show promise. A treatment algorithm for wAIHA is proposed to avoid the excessive use of corticosteroids.","PeriodicalId":12973,"journal":{"name":"Hematology. American Society of Hematology. Education Program","volume":"2022 1","pages":"105-113"},"PeriodicalIF":3.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821065/pdf/hem.2022000405.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10502554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"教育学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5